Angela M DeMichele, MD MSCE

faculty photo
Alan and Jill Miller Associate Professor in Breast Cancer Excellence
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
3 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent link

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Selected Publications

Tan AS, Nagler RH, Hornik RC, DeMichele A: Evolving information needs among colon, breast, and prostate cancer survivors: results from a longitudinal mixed- effects analysis. Cancer Epidemiol Biomarkers Prev 24: 1071-8, July 2015.

Brier MJ, Chambless D, Gross R, Su HI, DeMichele A, Mao JJ: Association between self-report adherence measures and oestrogen supression among breast cancer survivors on aromatase inhibitors. Eur J Cancer Epub ahead of print, July 2015.

DeMichele A, Chodosh LA: "Braking" the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res Epub ahead of print, July 2015.

Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D: Breast DCE-MRI kinetic heterogeneity tumor markers: Preliminary associates with neoadjuvant chemotherapy response. Transl Oncol June 2015.

Bauml J, Chen L, Chen J, Boyer J, Kalos M, Li SQ, DeMichele A, Mao JJ: Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with comorbid fatigue and insomnia? Breast Cancer Res 17: 89, June 2015.

Chung SH, Feldman MD, Martinez D, Kim H, Putt ME, Busch DR, Tchou J, Czerniecki BJ, Schnall MD, Rosen MA, DeMichele A, Yodh AG, Choe R: Macroscopic optical physiological parameters correlate with microscopic proliferation and vessel area breast cancer signatures. Breast Cancer Res 17: 72, May 2015.

Datta J, Berk E, Xu S, Fitzpatrick E, Rosemblit C, Lowenfeld, Goodman N, Lewis DA, Zhang PJ, Fisher C, Roses RE, DeMichele A, Czerniecki BJ: Anti- HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2- positive breast cancer. Breast cancer res 17: 71, May 2015.

DeMIchele A, Clark AS, Tan KS, Heitjan DF, Gramlich K, Gallagher M, Lal P, Feldman M, Zhang P, Colameco C, Lewis D, Langer M, Goodman N, Domchek S, Gogineni K, Rosen M, Fox K, O'Dwyer P: CDK4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety and Predictive Biomarker Assessment. Clinical Cancer Research 21(5): 995-1001, March 2015.

Melichar B, Adenis A, Lockhart AC, Bennouna J, Dees EC, Kayaleh O, Obermannova R, DeMichele A, Zatloukal P, Zhang B, Ullmann CD, Schusterbauer C.: Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small cell lung cancer, non small cell lung cancer, head and neck squamous carcinoma and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncology Epub ahead of print, February 2015.

White J, DeMichele A: Neoadjuvant therapy for breast cancer: controversies in clinical trial design and standard of care. Am Soc Clin Oncol Educ Book 35: 17-23, 2015.

back to top
Last updated: 07/28/2015
The Trustees of the University of Pennsylvania